Immune Pharmaceuticals Inc. - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immune Pharmaceuticals Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Immune Pharmaceuticals Inc. - Product Pipeline Review - 2015', provides an overview of the Immune Pharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immune Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immune Pharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immune Pharmaceuticals Inc.'s pipeline products

Reasons to buy

- Evaluate Immune Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immune Pharmaceuticals Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immune Pharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immune Pharmaceuticals Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Pharmaceuticals Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Immune Pharmaceuticals Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Immune Pharmaceuticals Inc. Snapshot 5
Immune Pharmaceuticals Inc. Overview 5
Key Information 5
Key Facts 5
Immune Pharmaceuticals Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Immune Pharmaceuticals Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Immune Pharmaceuticals Inc. - Pipeline Products Glance 14
Immune Pharmaceuticals Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Immune Pharmaceuticals Inc. - Early Stage Pipeline Products 16
IND/CTA Filed Products/Combination Treatment Modalities 16
Preclinical Products/Combination Treatment Modalities 17
Immune Pharmaceuticals Inc. - Drug Profiles 18
(amitriptyline + ketamine hydrochloride) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
bertilimumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
crolibulin 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
lidocaine hydrochloride 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
F-573 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Ferritizumab 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody Conjugate to Antagonize EGFR for Non-Small Cell Lung Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody Conjugate to Antagonize HER2 for Solid Tumors 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody Conjugate to Antagonize HER3 for Solid Tumors 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Immune Pharmaceuticals Inc. - Pipeline Analysis 32
Immune Pharmaceuticals Inc. - Pipeline Products by Target 32
Immune Pharmaceuticals Inc. - Pipeline Products by Route of Administration 34
Immune Pharmaceuticals Inc. - Pipeline Products by Molecule Type 35
Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 36
Immune Pharmaceuticals Inc. - Recent Pipeline Updates 37
Immune Pharmaceuticals Inc. - Dormant Projects 43
Immune Pharmaceuticals Inc. - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
histamine dihydrochloride 44
verubulin 44
Immune Pharmaceuticals Inc. - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Immune Pharmaceuticals Inc., Key Information 5
Immune Pharmaceuticals Inc., Key Facts 5
Immune Pharmaceuticals Inc. - Pipeline by Indication, 2015 7
Immune Pharmaceuticals Inc. - Pipeline by Stage of Development, 2015 9
Immune Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015 10
Immune Pharmaceuticals Inc. - Combination Treatment Modalities in Pipeline, 2015 11
Immune Pharmaceuticals Inc. - Partnered Products in Pipeline, 2015 12
Immune Pharmaceuticals Inc. - Partnered Products/ Combination Treatment Modalities, 2015 13
Immune Pharmaceuticals Inc. - Phase II, 2015 14
Immune Pharmaceuticals Inc. - Phase I, 2015 15
Immune Pharmaceuticals Inc. - IND/CTA Filed, 2015 16
Immune Pharmaceuticals Inc. - Preclinical, 2015 17
Immune Pharmaceuticals Inc. - Pipeline by Target, 2015 33
Immune Pharmaceuticals Inc. - Pipeline by Route of Administration, 2015 34
Immune Pharmaceuticals Inc. - Pipeline by Molecule Type, 2015 35
Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2015 36
Immune Pharmaceuticals Inc. - Recent Pipeline Updates, 2015 37
Immune Pharmaceuticals Inc. - Dormant Developmental Projects,2015 43
Immune Pharmaceuticals Inc. - Discontinued Pipeline Products, 2015 44
Immune Pharmaceuticals Inc., Other Locations 45
Immune Pharmaceuticals Inc., Subsidiaries 45